-$0.91 EPS Expected for Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) This Quarter

Analysts expect Rhythm Pharmaceuticals Inc (NASDAQ:RYTM) to announce earnings per share (EPS) of ($0.91) for the current fiscal quarter, Zacks reports. Zero analysts have issued estimates for Rhythm Pharmaceuticals’ earnings. The lowest EPS estimate is ($1.06) and the highest is ($0.74). Rhythm Pharmaceuticals reported earnings of ($0.74) per share in the same quarter last year, which would suggest a negative year-over-year growth rate of 23%. The business is scheduled to issue its next quarterly earnings report on Friday, March 13th.

According to Zacks, analysts expect that Rhythm Pharmaceuticals will report full-year earnings of ($4.00) per share for the current year, with EPS estimates ranging from ($4.19) to ($3.82). For the next fiscal year, analysts forecast that the company will report earnings of ($3.38) per share, with EPS estimates ranging from ($4.05) to ($3.06). Zacks Investment Research’s EPS averages are a mean average based on a survey of sell-side analysts that cover Rhythm Pharmaceuticals.

Rhythm Pharmaceuticals (NASDAQ:RYTM) last issued its earnings results on Friday, November 1st. The company reported ($1.04) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.06) by $0.02.

Several equities analysts have recently weighed in on RYTM shares. BidaskClub upgraded shares of Rhythm Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Tuesday, October 22nd. Cowen restated a “buy” rating and issued a $40.00 target price on shares of Rhythm Pharmaceuticals in a research note on Wednesday, September 25th. LADENBURG THALM/SH SH reaffirmed a “buy” rating and set a $43.00 price target on shares of Rhythm Pharmaceuticals in a research note on Monday, September 9th. Finally, Zacks Investment Research upgraded Rhythm Pharmaceuticals from a “hold” rating to a “buy” rating and set a $25.00 price target on the stock in a report on Thursday. One analyst has rated the stock with a sell rating and seven have issued a buy rating to the stock. The company has a consensus rating of “Buy” and an average price target of $36.50.

In other Rhythm Pharmaceuticals news, Director Todd Foley sold 102,682 shares of the firm’s stock in a transaction on Friday, November 22nd. The shares were sold at an average price of $21.78, for a total value of $2,236,413.96. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. In the last 90 days, insiders have sold 444,075 shares of company stock worth $9,935,520. Corporate insiders own 4.45% of the company’s stock.

Institutional investors and hedge funds have recently modified their holdings of the business. SG Americas Securities LLC bought a new position in shares of Rhythm Pharmaceuticals in the third quarter valued at approximately $1,547,000. DekaBank Deutsche Girozentrale purchased a new stake in Rhythm Pharmaceuticals in the 2nd quarter valued at $564,000. Susquehanna International Group LLP bought a new position in Rhythm Pharmaceuticals during the 2nd quarter valued at $328,000. Rice Hall James & Associates LLC lifted its stake in Rhythm Pharmaceuticals by 172.5% during the 2nd quarter. Rice Hall James & Associates LLC now owns 63,217 shares of the company’s stock valued at $1,391,000 after acquiring an additional 40,015 shares in the last quarter. Finally, Fosun International Ltd boosted its holdings in Rhythm Pharmaceuticals by 37.0% during the 2nd quarter. Fosun International Ltd now owns 40,720 shares of the company’s stock worth $883,000 after acquiring an additional 11,000 shares during the last quarter. 78.13% of the stock is owned by hedge funds and other institutional investors.

NASDAQ:RYTM traded up $0.54 during trading hours on Friday, reaching $24.41. The company had a trading volume of 268,295 shares, compared to its average volume of 183,634. Rhythm Pharmaceuticals has a twelve month low of $18.00 and a twelve month high of $31.94. The company has a quick ratio of 6.78, a current ratio of 6.78 and a debt-to-equity ratio of 0.02. The firm has a market cap of $1.07 billion, a price-to-earnings ratio of -10.21 and a beta of 0.66. The business’s 50-day simple moving average is $22.02 and its two-hundred day simple moving average is $22.09.

Rhythm Pharmaceuticals Company Profile

Rhythm Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of therapeutics for the treatment of rare genetic disorders that result in life-threatening metabolic disorders. The company's lead product candidate is setmelanotide, a melanocortin-4 receptor agonist peptide, which is in Phase III clinical trials to treat pro-opiomelanocortin (POMC) and leptin receptor deficiency obesity, and Bardet-Biedl and Alström syndrome; and is in Phase II clinical trials for treating POMC heterozygous deficiency obesity and POMC epigenetic disorders.

Further Reading: Market Timing

Get a free copy of the Zacks research report on Rhythm Pharmaceuticals (RYTM)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Rhythm Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Rhythm Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.